Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 4/20 | 0.67 |
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.62 |
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.62 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.62 |
| ▸ | F10 | P00742 | 2/20 | 0.61 |
| ▸ | CRHBP | P24387 | 1/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8717056 | 0.88 | PLK1 (0.80) | PLK1CA1CA2NPC1RAB9A | |
| SCHEMBL12858639 | 0.85 | CRHBP (0.66) | PLK1CA1CA2NPC1RAB9A | |
| SCHEMBL27521416 | 0.82 | PLK1 (0.71) | PLK1CA1CA2NPC1RAB9A | |
| SCHEMBL6996017 | 0.82 | PLK1 (0.71) | PLK1CA1CA2NPC1RAB9A | |
| SCHEMBL7915810 | 0.82 | PLK1 (0.71) | PLK1CA1CA2NPC1RAB9A | |
| SCHEMBL837307 | 0.82 | PLK1 (1.00) | PLK1CA1CA2NPC1RAB9A | |
| SCHEMBL15328092 | 0.81 | GAA (0.54) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL28690251 | 0.81 | NPC1 (0.71) | PLK1CA1CA2NPC1RAB9A | |
| SCHEMBL407188 | 0.80 | CA1 (1.00) | PLK1CA1CA2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL11037223 | 0.80 | PLK1 (0.96) | PLK1CA1CA2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | claimed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | claimed |
| CN-104302287-A | Indolin-2-one derivatives as protein kinase inhibitors | ANNJI PHARM CO LTD | 2015-01-21 | — | — | CN | claimed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | claimed |
| CN-113041221-B | ROS (reactive oxygen species) sensitivity and H2Preparation method and application of S donor response type nano micelle | 潍坊中医药产业技术研究院 | 2022-11-01 | — | — | CN | disclosed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| CN-104302287-A | Indolin-2-one derivatives as protein kinase inhibitors | ANNJI PHARM CO LTD | 2015-01-21 | — | — | CN | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
| US-5106843-A | Treatment of migraine, emesis, anxiety, gastrointestinal disorders, psychological disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0323077-B1 | HETEROCYCLIC COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1991-09-11 | — | — | EP | disclosed |
| US-4983600-A | Antiemetics, antianxiety agents, gastrointestinal disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-08 | — | — | US | disclosed |
| EP-0323077-A1 | Heterocyclic compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ING2, CDK2, MAP3K20 | PLK1 34/4885CA1 4827/4885CA2 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.